Axsome Therapeutics Stock News

Axsome's two new products are seeing prescription growth. The company aims to launch four more products in just a couple of years.

Axsome Therapeutics shares soared more than 100% last year after its first two products launched. It may have more on the way.

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Axsome Therapeutics is a rising star in biotech. Pfizer is too cheap to pass up.

Teladoc and Axsome offer solid growth potential and are in the early days of their growth stories. Pfizer offers passive income while investors wait for this pharma-giant's new phase of growth to begi

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea Cognitive improvement with Sunosi sustained over eight hours i

Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with

CRISPR Therapeutics is awaiting approval for a potential multi-billion product. Axsome Therapeutics has several clinical and regulatory milestones ahead.

Axsome has two approved treatments as well as candidates in late-stage development Vertex has the dominant treatment for cystic fibrosis and is developing other products.

Sanofi's wide lineup of medicines across several therapeutic areas makes it attractive. Axsome Therapeutics is rising in prominence thanks to an exciting pipeline.

Axsome has several catalysts in the works that could boost its stock price. Exelixis is working on new drugs to expand its footprint in oncology.

The partnership of Otsuka Pharmaceutical and Lundbeck beat Axsome to market with the first approved treatment for Alzheimer's disease agitation. Axsome reported strong clinical trail data from its can

Axsome's relatively new approval was only the first step in an exciting growth story. Eli Lilly has a strong pipeline that will help improve its already-solid financial results.

Investing in growth stocks can be far less risky if you make smaller, more frequent purchases of your favorite companies. Axsome Therapeutics is a commercial-stage drugmaker that recently launched a n